The developing brain is uniquely susceptible to drug-induced increases in programmed cell death or apoptosis. Many compounds, including anticonvulsant drugs, anesthetic agents, and ethanol, when administered in a narrow postnatal window in rodents, result in increased pruning of neurons. Here, we report that dimethyl sulfoxide (DMSO) triggers widespread neurodegeneration in the immature (postnatal day, P7) rat brain, an effect consistent with a prior report in neonatal mice. We found that the synthetic cannabinoid receptor agonist WIN 55,212-2 (WIN) exerts a neuroprotective effect against DMSO-induced cell death. We extended these findings to determine if WIN is neuroprotective against another drug class known to increase developmental cell death, namely antiseizure drugs. The antiseizure drug phenobarbital (PB) remains the primary treatment for neonatal seizures, despite significantly increasing cell death in the developing rodent brain. WIN exerts antiseizure effects in immature rodent seizure models, but increases the toxicity associated with neonatal ethanol exposure. We thus sought to determine if WIN would protect against or exacerbate PB-induced cell death. Unlike either the prior report with ethanol or our present findings with DMSO, WIN was largely without effect on PB-induced cell death. WIN alone did not increase cell death over levels observed in vehicle-treated rats. These data suggest that WIN has a favorable safety profile in the developing brain and could potentially serve as an adjunct therapy with phenobarbital (albeit one that does not attenuate PB-induced toxicity).
Introduction
Programmed cell death, or apoptosis, is a tightly regulated process that is essential for network development and homeostasis in the developing brain; cells that make appropriate synaptic connections are maintained, whereas those that fail to wire appropriately are pruned (Elmore 2007) . During development, apoptosis in the rodent brain exhibits high temporal specificity with peak programmed cell death detected between postnatal day (P) 2 and the end of the first postnatal week (Ferrer et al. 1992) . After P7, the rate of apoptosis dramatically decreases into the second week, and developmental cell death is undetectable by the end of the first month (Ferrer et al. 1992) .
During this period of developmental vulnerability, a variety of compounds that suppress synaptic transmission can potentiate ongoing apoptosis. Exposure to several drug classes, including ethanol (Ikonomidou et al. 2000; Olney et al. 2004; Hansen et al. 2008) , anxiolytics (Ikonomidou et al. 2000; Olney et al. 2004) , anesthetics (Ikonomidou et al. 1999; Jevtovic-Todorovic et al. 2003) , and some (but not all) anticonvulsants (Bittigau et al. 2003; Bittigau et al. 2006; Forcelli et al. 2011) , significantly increase cell death during the first postnatal week. Similarly, dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system (CNS) of mice with vulnerability to degeneration peaking at P7 (Hanslick et al. 2009 ). This profile is strikingly different from that observed in the adult brain, where these agents do not trigger apoptosis, and in some cases, actually exert neuroprotective effects.
For example, in adult animal models of traumatic brain injury, spinal cord injury, and stroke, DMSO has been reported to significantly reduce cell death and damage (Bardutzky et al. 2005; Giorgio et al. 2008; Jacob and de la Torre 2009) . Developmentally restricted increases in cell death by otherwise neuroprotective agents are not a wholly new phenomenon. Plant-based and synthetic cannabinoids have demonstrated neuroprotective effects in several neurodegenerative disease models (Ramírez et al. 2005; Gowran et al. 2011; Sánchez and García-Merino 2012; Concannon et al. 2015; Bisogno et al. 2016) . Cannabinoid receptor agonists can potentiate developmental neurotoxicity induced by other compounds but have no proapoptotic effect alone despite the early ontogeny of the cannabinoid system and reported neuroprotective effects in adult animals (Harkany et al. 2007; Hansen et al. 2008) . For example, in P7 mice, administration of the mixed CB1/CB2 receptor synthetic agonist WIN 55,212-2 (WIN) did not increase cell death compared to that in vehicle controls (Hansen et al. 2008) . However, WIN dosedependently increased the apoptotic response induced by ethanol administration in these animals (Hansen et al. 2008) . Given the increasing interest in cannabinoids as therapeutic agents for neonatal seizures, a more detailed toxicity profile is needed.
Provided the pattern of age-dependent toxicity of otherwise neuroprotective agents and the report of potentiated cell death by cannabinoid agonists, we aimed to (1) confirm that DMSO increases developmental cell death in P7 rats and (2) determine if DMSO-or PB-induced cell death would be altered by co-treatment with the cannabinoid agonist WIN.
Methods

Animals
Female Sprague-Dawley rats with male pups were obtained from Harlan/Envigo (Envigo, Frederick, MD, USA) and were delivered to the Division of Comparative Medicine at Georgetown University at postnatal day (P) 5. On P7, pups were treated, returned to the dam, and allowed to survive for 24 h before tissue collection. A total of 120 pups, derived from 12 litters, were used for the present experiments.
For all experiments, treatments were counterbalanced within and across litters. Animals were maintained in temperaturecontrolled (21°C) rooms with a 12-h light cycle and food (Lab Diet #5001) and water available ad libitum in the Georgetown University Division of Comparative Medicine. All experimental manipulations occurred during the light phase. Experimental procedures were performed in compliance with the Association for Assessment and Accreditation of Laboratory Animal Care standards and were approved by the Georgetown University Animal Care and Use Committee.
Drug Preparation
All drug treatments were administered intraperitoneally (ip) at a volume of 10 ml/kg. WIN 55,212-2 (Cayman Chemical, Ann Arbor, MI, USA) was prepared in either 100% dimethyl sulfoxide (DMSO) or a vehicle (VEH) solution of ethanol:Kolliphor:0.9% saline (2:1:17; Sigma-Aldrich, St. Louis, MO, USA) in concentrations of 0.1, 0.3, or 1.0 mg/ ml (corresponding to doses of 1, 3, and 10 mg/kg, respectively; Hansen et al. 2008; Huizenga et al. 2017) . We have previously reported that 1-3 mg/kg of WIN protects immature animals from seizures evoked by methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) and pentylenetetrazole (PTZ; Huizenga et al. 2017) . Phenobarbital (PB, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 0.9% saline at a concentration of 75 mg/ml (corresponding to a dose of 75 mg/kg). This dose has been demonstrated to exert antiseizure efficacy against PTZinduced seizures in P7 rat pups (Kubova and Mares 1991; Forcelli et al. 2013) . Moreover, this dose of PB robustly increases cell death above developmental levels (Bittigau et al. 2006; Forcelli et al. 2011) . Drug combination treatments were administered in a single injection.
Drug Treatment
P7 pups were randomly assigned to receive a single dose of DMSO, WIN (1, 3, or 10 mg/kg in DMSO), saline, PB (75 mg/ kg in saline), vehicle (VEH; 2:1:17 ethanol:Kolliphor:saline), WIN (1, 3, or 10 mg/kg in vehicle), or a combination of WIN (3 or 10 mg/kg in vehicle) plus PB (75 mg/kg).
Tissue Preparation
Twenty-four hours after drug treatment, pups were perfused transcardially with phosphate buffered saline (pH 7.4, 10 ml; Thermo Fisher Scientific, Waltham, MA, USA) followed by 4% paraformaldehyde (10 ml; Sigma-Aldrich, St. Louis, MO, USA). This survival interval was based on prior reports examining drug-related apoptosis in the developing brain Kim et al. 2007 ). Brains were removed and postfixed for 24 h before transferred to 30% sucrose for at least 72 h before cryosectioning. Forty micrometer thick coronal sections were mounted and stained for Fluoro-Jade B as described below.
Fluoro-Jade B Staining
Forty micrometer coronal sections were stained using the Fluoro-Jade B histological staining protocol (Histo-Chem Inc., Jefferson, AR, USA) to fluorescently label neurons undergoing degeneration. Slides were first immersed in a solution containing 1% sodium hydroxide in 80% ethanol for 5 min. Next, slides were transferred to 70% ethanol followed by distilled water for 2 min each. Then, slides were transferred to a 0.06% potassium permanganate solution in distilled water for 5-10 min. After a 2-min rinse in distilled water, slides were immersed in the Fluoro-Jade B (EMD Millipore, Burlington, MA, USA) staining solution with a final dye concentration of 0.0004%, for 15 min. Lastly, the slides were rinsed 3 times for 1 min each before dried, cleared by at least 1 min of xylene immersion, and coverslipped using Cytoseal 60 (Thermo Fisher Scientific, Waltham, MA, USA) mounting media.
Microscopy
Fluorescent photomicrographs were collected on a Nikon 80i microscope with a QImaging QIClick camera. Images at × 10 magnification of three sequential sections at 200 μm intervals for each brain region were taken. Brain regions were defined using the neonatal rat brain atlas of Ramachandra and Subramanian (Ramachandra and Subramanian 2011) and selected based on prior reports of antiseizure drug-induced enhancements in cell death from our lab (Forcelli et al. 2011; Kaushal et al. 2016; Brown et al. 2016 ) and others (Bittigau et al. 2006) . Quantification of neurodegeneration within each region was performed by manual counting of the FluoroJade B positive cells within the anatomical boundaries for each brain regions. Cell counting was performed using IMAGEJ software (National Institutes of Health, Bethesda, MD, USA). For analysis, the mean number of degenerating (Fluoro-Jade B positive) cells for each region in each animal was calculated from the three sequential sections. Microscopy and analysis were performed by investigators blinded to treatment conditions.
Statistics
Statistical analyses were performed using GraphPad Prism 7.0c (GraphPad Software; La Jolla, CA, USA). Cell death analyses were analyzed using one-way ANOVA with multiple comparisons corrected for by Sidak and Holm-Sidak's multiple comparisons test. Probability values < 0.05 were considered statistically significant. One statistical outlier (treated with the highest dose of WIN + DMSO) was identified using the ROUT algorithm (Q = 0.1%) and was removed.
Results
Effect of WIN on DMSO-Induced Cell Death
DMSO has been shown to induce neuronal toxicity, particularly during vulnerable periods of development (Hanslick et al. 2009 ). To determine the effect of CB receptor agonism on DMSO-induced cell death, we quantified Fluoro-Jade B positive cells after treatment with WIN dissolved in DMSO (1, 3, and 10 mg/kg). In line with a prior report that found DMSO increases developmental apoptosis (Hanslick et al. 2009 ), we found DMSO alone increases neuronal cell death across the developing brain as compared to saline treatment. This effect was striking, with 8-to 26-fold increases in cell death observed. Administration of WIN resulted in a dose-dependent decrease in DMSO-induced cell death in cortical brain regions ( Fig. 1 ). There was a significant treatment effect in the cingulate cortex (ANOVA, F 4,37 = 6.47, p = 0.0005; Fig. 1a ), motor cortex (ANOVA, F 4,30 = 11.99, p < 0.0001; Fig. 1b) , and somatosensory cortex (ANOVA, F 4,30 = 14.73, p < 0.0001; Fig. 1c ). Sidak's multiple comparisons test revealed that DMSO significantly increased cell death compared to salinetreated controls in the cingulate (p = 0.0004), motor (p < 0.0001), and somatosensory (p < 0.0001) cortices. WIN, when given at a dose of 10 mg/kg, significantly decreased the DMSO-induced cell death in the cingulate (p = 0.0084) and motor cortices (p = 0.0005). In the somatosensory cortex, WIN reduced DMSO-induced cell death at both the 3 mg/kg (p = 0.0157) and 10 mg/kg (p = 0.0003) doses.
In subcortical regions, we observed a similar pattern ( Fig. 2) : there was a significant main effect of drug treatment in striatum (ANOVA, F 4,29 = 8.10, p = 0.0002; Fig. 2a ), lateral thalamus (ANOVA, F 4,30 = 24.72, p < 0.0001; Fig. 2b ), and lateral septum (ANOVA, F 4,35 = 6.39, p = 0.0006; Fig. 2c ). Sidak's multiple comparisons test confirmed that DMSO significantly increased cell death in the striatum (p < 0.0001), lateral thalamus (p < 0.0001), and lateral septum (p = 0.0002), as compared to saline-treated controls. As in the cortical regions, the 10 mg/kg dose of WIN significantly decreased DMSO-induced cell death in the striatum (p = 0.0049) and lateral thalamus (p = 0.0005). WIN was without effect on DMSO-increased cell death in the lateral septum.
Effect of WIN Alone, and in Combination with PB, on Cell Death
The neuroprotective effect of WIN against DMSO-induced cell death led us to next examine if (1) WIN, when administered in an inert vehicle, impacts basal levels of cell death in the developing brain and (2) if WIN would attenuate the cell death caused by a common antiseizure medication, phenobarbital.
When prepared in an inert vehicle solution (VEH, see BMethods^section), WIN alone did not modify cell death from the levels seen in vehicle-treated controls (Figs. 3, 4 , and 5). However, as expected, phenobarbital exposure caused a significant increase in the number of Fluoro-Jade B positive cells in each region analyzed. This increase in degenerating cells ranged from 2.5-to 10-fold above saline-treated controls. This is a similar increase to that previously reported following PB exposure (Bittigau et al. 2006; Forcelli et al. 2011; Kaushal et al. 2016; Brown et al. 2016) .
These effects were confirmed by one-way analysis of variance, which revealed significant treatment effects in each brain region analyzed (cingulate cortex, F 7,55 = 9.67, p < 0.0001; motor cortex, F 7,48 = 20.01, p < 0.0001; somatosensory cortex, F 7,48 = 21.39, p < 0.0001; striatum, F 7,47 = 32.72, p < 0.0001; lateral thalamus, F 7,48 = 68.32, p < 0.0001; lateral septum, F 7,46 = 11.48, p < 0.0001). These effects were driven by PB exposure, a finding consistent with prior reports. In each region, Holm-Sidak corrected pairwise comparisons revealed significant differences between the PB-treated group and the saline-treated groups for each region (cingulate cortex, p = 0.0004, Fig. 3a ; motor cortex, p < 0.0001, Fig. 3b ; somatosensory cortex, p < 0.0001, Fig. 4a ; striatum, p < 0.0001, Fig. 4b ; lateral thalamus, p < 0.0001, Fig. 5a ; lateral septum, p = 0.0002, Fig. 5b) .
Surprisingly, despite the robust effect of WIN against DMSO-induced cell death, the effects of WIN against PBinduced cell death were limited. Only within the cingulate cortex, and only at the 10 mg/kg dose, did WIN significantly reduce cell death compared to PB alone (Holm-Sidak, p = In the motor cortex, a different pattern was observed. While PB significantly increased cell death above saline control levels (Holm-Sidak, p < 0.0001), co-treatment with WIN (10 mg/kg) produced a small but significant exacerbation of injury (Holm-Sidak, p = 0.0447; Fig. 3b ).
In the somatosensory cortex and striatum, PB alone (p < 0.0001) and in combination with WIN (3 and 10 mg/kg) produced significant increases in cell death compared to vehicle (Holm-Sidak, p < 0.0001) and saline controls (Holm-Sidak, p < 0.0001; Fig. 4a and b) . Co-treatment with WIN did not produce an effect that differed from that of PB alone. The same pattern was observed in lateral thalamus and lateral septum. PB alone (p < 0.0001) and in combination with WIN (3 and 10 mg/kg) produced significant increases in cell death compared to vehicle (lateral thalamus: WIN 3 + PB 75, p < 0.0001, WIN 10 + PB 75, p < 0.0001; lateral septum: WIN 3 + PB 75, p = 0.0010, WIN 10 + PB 75, p = 0.0014) and salinetreated controls (lateral thalamus: WIN 3 + PB 7, p < 0.0001, WIN 10 + PB 75, p < 0.0001; lateral septum: WIN 3 + PB 75, p = 0.0009, WIN 10 + PB 75, p = 0.0013; Fig. 5a and b) .
Discussion
Here, we evaluated the toxicity and neuroprotective potential of DMSO, phenobarbital, and the CB1/2 receptor agonist This profile of enhanced neurodegeneration with DMSO is consistent with a prior report indicating DMSO increases apoptosis in developing mice (Hanslick et al. 2009 ). In that report, DMSO-induced apoptosis (as measured through activated caspase-3 immunohistochemistry and electron microscopy) was most prominent in the first two postnatal weeks (Hanslick et al. 2009 ). Toxicity was evident with doses of DMSO as low as 0.3 ml/kg, with maximal effects seen at 10 ml/kg doses (which is the dose we used in the present study). DMSO is an organic solvent often used as a vehicle for drug delivery in preclinical studies, and these data indicate that it should not be considered biologically inert.
While the mechanisms by which DMSO induces cell death in developing animals are unknown, the phenomena appear similar to that observed after early exposure to sedative, anxiolytic, anesthetic, and anticonvulsant drugs. First, as with these other drugs, DMSO-induced cell death occurs during a restricted developmental period, primarily during the first two postnatal weeks (Hanslick et al. 2009 ). Second, a central hypothesis behind drug-induced apoptosis is the suppression of network activity. During development, neurons are suggested to require synaptic input to allow them to integrate into a functioning neuronal network. Network integration is a requirement for survival, and suppression of activity consequently increases apoptosis (Heck et al. 2008) . Furthermore, blockade of NMDA receptors triggers apoptotic neurodegeneration, supporting the idea that network activity suppresses an apoptotic response to encourage functional network development (Ikonomidou et al. 1999; Dikranian et al. 2001) . Consistent with this hypothesis, DMSO suppresses NMDAand AMPA-mediated currents in cultured hippocampal neurons (Lu and Mattson 2001) . GABA, glutamate, and acetylcholine receptor activity are also reduced by DMSO (Sawada and Sato 1975; Hülsmann et al. 1999) suggesting that suppression of synaptic transmission may be a mechanism underlying its developmental toxicity. We found that the CB1/2 receptor agonist WIN 55,212-2, which is commonly dissolved in DMSO, produced a dosedependent neuroprotective effect against DMSO-induced cell death. This is interesting in light of a prior report of WIN enhancing developmental apoptosis triggered by ethanol (Hansen et al. 2008) . Cannabinoid receptor agonists have been reported to display CB1 receptor-mediated neuroprotective effects by lowering extracellular glutamate to inhibit excitotoxic release (Shen et al. 1996; Szabo et al. 2000; Gerdeman and Lovinger 2001; Robbe et al. 2001 ) and through HINT1-mediated modulation of NMDA receptor (Vicente- Sánchez et al. 2013; Sánchez-Blázquez et al. 2013) . Along these lines, WIN has been reported to protect against a variety of excitotoxic insults, including glutamate (Shen et al. 1996) , 3-nitropropionic acid (3-NP; Maya-López et al. 2017), and quinolinic acid toxicity (Rangel-López et al. 2015) . However, these effects likely do not explain the neuroprotective effects of WIN in the present study, as rather than excitotoxic injury, PB-and DMSO-induced damage likely results from a suppression of activity.
Together, these data provide comprehensive evidence of extensive neuroprotective effects via CB receptor activation. In fact, the endocannabinoid system itself appears to play a role in the brain response to injury: both the CB1 receptor and its endogenous ligand anandamide increase in early postnatal rats following injury or NMDA receptor blockade (Hansen et al. 2001; Marsicano et al. 2003; Mechoulam and Parker 2013) . Although principally expressed in peripheral immune cells, CB2 receptors are also expressed in select neuronal populations, and receptor activation can promote neuronal survival by modulating the release of immunomodulators from astrocytes and microglial cells to inhibit excitotoxicity, oxidative stress, and neuronal apoptosis (Mechoulam and Parker 2013; Bisogno et al. 2016) . Therefore, WIN activation of both CB1 and CB2 receptors underlies the neuroprotective effects that we detected. A considerable amount of research reveals a strong and consistent proapoptotic effect of the anticonvulsant drug, phenobarbital (PB) on the developing rodent brain Bittigau et al. 2006; Ikonomidou 2009; Forcelli et al. 2011; Kaushal et al. 2016; Brown et al. 2016) . PB is a positive allosteric modulator of the GABA A receptor, which results in a suppression of neuronal activity. As described above, suppression of neurotransmission during synaptogenesis in the developing brain triggers enhanced apoptosis (Olney et al. 2004; Bittigau et al. 2006; Ikonomidou 2009) . PB is of particular interest, as it is the current first-line treatment for neonatal seizures (World Health Organization et al. 2011) , despite its toxicity in the developing brain, even at therapeutically relevant doses (Kubova and Mares 1991; Bittigau et al. 2006; Forcelli et al. 2011) . This underscores the importance of identifying adjunct therapies that can mitigate the neurotoxicity of PB without sacrificing its antiseizure effects.
We recently described the antiseizure efficacy of CB1 receptor agonists in multiple models of seizures in developing animals (Huizenga et al. 2017) . WIN, in particular, significantly reduced seizure severity in three different epilepsy models in P10 rats (Huizenga et al. 2017) . The antiseizure effect of WIN in developing animals, together with its neuroprotective effect against DMSO-induced cell death, led us to examine if WIN, in combination with PB, would reduce PBinduced cell death. However, unlike the protective effect WIN exerted against DMSO-induced cell death, it produced a mixed effect against PB-induced cell death. In one brain region WIN increased PB-induced cell death, in another it decreased it, and in the remaining regions it was without effect. The mechanism behind this region-specificity is unknown, but unlikely related to CB receptor expression as the receptors are expressed early in development, and WIN was effective in all regions examined against DMSO-induced cell death. The combined administration of WIN and PB did not exhibit a consistent enhancement in cell death similar to the widespread apoptosis seen with PB and Δ 9 -tetrahydrocannabinol (THC; Hansen et al. 2008) . One reason for this difference could be a result of the multimodal mechanism of action of THC compared to the CB receptor specificity of WIN. Despite both acting at the CB1 receptor, THC is only a partial agonist and has been shown to transiently activate and desensitize the transient receptor potential (TRP) family of receptors (Felder et al. 1995; Pertwee 2008; De Petrocellis et al. 2011) . Additionally, THC is reported to antagonize the action of endogenous ligands, which could effectively blunt any otherwise neuroprotective response from endocannabinoid production and signaling (Pertwee 2008) . However, further studies are required to delineate the role of the complex cannabinoid signaling during development, in response to pathological conditions and in conjunction with other compounds.
Here, we have shown the cannabinoid receptor agonist WIN displays neuroprotective effects against toxicity induced by neonatal DMSO administration. This effect was selective and did not extend to toxicity induced by neonatal PB exposure. These data are relevant to both research and clinical practice, as WIN is sparingly soluble in aqueous solvents and is recommended by the manufacturer to be wholly or initially dissolved in organic solvents such as DMSO or ethanol (Caymen Chemical, Ann Arbor, MI, USA). However, provided the biological activity of both DMSO and ethanol alone, especially in the developing brain, careful attention should be paid to the source of any detected experimental outcomes when using either as a drug solvent. Additionally, with a growing interest and use of CB-targeted compounds for pediatric epilepsy (Friedman and Devinsky 2015) , the neurodevelopmental toxicity of DMSO limits its clinical use as a solvent. While the precise mechanisms of WIN's neuroprotective action remain unknown, these data underscore its potential as a neuroprotective agent against select insults during critical periods of brain development.
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